Mylan NV (NASDAQ:MYL)

39.21
Delayed Data
As of 4:00pm ET
 -0.34 / -0.86%
Today’s Change
29.39
Today|||52-Week Range
47.82
-7.33%
Year-to-Date
Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1
May 16 / Zacks.com - Paid Partner Content
Economic Data & More
May 09 / Zacks.com - Paid Partner Content
Delek Group, Ltd. Buys Ormat Technologies Inc, Nutrien, Shire PLC, Sells Noble Energy...
May 16 / GuruFocus News - Paid Partner Content
Mylan Misses on Earnings and Sales in Q1
May 09 / Zacks.com - Paid Partner Content
Mylan (MYL) Q1 Earnings Lag on Weak North America Sales
May 09 / Zacks.com - Paid Partner Content
Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline
May 09 / Zacks.com - Paid Partner Content
PPI Just +0.1%, Boeing to Take Hit from Iran Pullout
May 09 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close39.55
Today’s open39.74
Day’s range39.13 - 40.07
Volume2,819,859
Average volume (3 months)4,847,833
Market cap$19.7B
Data as of 4:00pm ET, 05/22/2018

Growth & Valuation

Earnings growth (last year)+41.30%
Earnings growth (this year)+17.63%
Earnings growth (next 5 years)+6.30%
Revenue growth (last year)+7.06%
P/E ratio29.0
Price/Sales1.91
Price/Book1.51

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...-1.75-1.96%
PRGOPerrigo Company PLC+0.28+0.37%
JAZZJazz Pharmaceuticals...+1.04+0.63%
ALNYAlnylam Pharmaceutic...-1.84-1.83%
Data as of 4:02pm ET, 05/22/2018

Financials

Next reporting dateAugust 9, 2018
EPS forecast (this quarter)$1.24
Annual revenue (last year)$11.9B
Annual profit (last year)$696.0M
Net profit margin5.85%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Director
Heather M. Bresch
President &
Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts